HEAL — Restart Life Sciences Income Statement
0.000.00%
Last trade - 00:00- CA$3.42m
- CA$3.16m
Annual income statement for Restart Life Sciences, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.011 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0.002 | 0 | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 25.2 | 2.93 | 1.94 | 1.26 | 0.277 |
| Operating Profit | -25.2 | -2.93 | -1.94 | -1.26 | -0.277 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -25.2 | -2.68 | -2.47 | -1.22 | 0.225 |
| Net Income After Taxes | -25.2 | -2.68 | -2.47 | -1.22 | 0.225 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -25.2 | -2.68 | -2.47 | -1.22 | 0.225 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -25.2 | -2.68 | -2.47 | -1.22 | 0.225 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.353 | -0.242 | -0.181 | -0.083 | -0.049 |